Global Information
회사소개 | 문의

세계의 재생의료 시장 분석과 예측(-2022년) : 줄기세포, 조직공학, 바이오뱅크, CAR-T 산업

Global Regenerative Medicine Market Analysis & Forecast to 2022; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

리서치사 Kelly Scientific Publications
발행일 2018년 06월 상품 코드 493934
페이지 정보 영문 682 Pages
가격
US $ 4,900 ₩ 5,531,100 PDF by E-mail (Single User License)
US $ 9,800 ₩ 11,062,200 PDF by Email - Mid Level License (up to 10 people)
US $ 14,700 ₩ 16,593,300 PDF by E-mail - Enterprise Wide License


세계의 재생의료 시장 분석과 예측(-2022년) : 줄기세포, 조직공학, 바이오뱅크, CAR-T 산업 Global Regenerative Medicine Market Analysis & Forecast to 2022; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries
발행일: 2018년 06월 페이지 정보 : 영문 682 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계의 재생의료 시장 규모는 2016년의 189억 달러에서 2022년에는 660억 달러 이상의 규모로 확대될 것으로 예측됩니다.

세계의 재생의료 시장을 분석했으며, 애플리케이션·지역별 시장 분석, 주요 기업의 출시/파이프라인 제품 개요·재무 분석·사업 전략, 현재 동향, 사업 환경, 파이프라인 제품, 임상시험 및 향후 예측 등에 대해 정리하여 전해드립니다.

제1장 조사 개요

제2장 서론

제3장 줄기세포·임상시험

  • 서론
  • 다능성 줄기세포
  • 신경 줄기세포
  • 내피 줄기세포 또는 전구세포
  • 태반 줄기세포
  • 왜 줄기세포 시험은 실패하는가?
  • 줄기세포 임상시험의 미래는?
  • 최첨단 줄기세포 임상시험
  • Ocata Therapeutics의 현재 줄기세포 임상시험
  • CHA Biotech의 현재 줄기세포 임상시험
  • Pfizer의 현재 줄기세포 임상시험
  • GSK의 현재 줄기세포 임상시험
  • Bayer의 현재 줄기세포 임상시험
  • Mesoblast International의 현재 줄기세포 임상시험
  • Millennium Pharmaceutical의 현재 줄기세포 임상시험
  • AstraZeneca의 현재 줄기세포 임상시험
  • Merck의 현재 줄기세포 임상시험
  • Chimerix의 현재 줄기세포 임상시험
  • Eisai의 현재 줄기세포 임상시험
  • SanBio의 현재 줄기세포 임상시험
  • Celgene의 현재 줄기세포 임상시험
  • StemCells의 현재 줄기세포 임상시험
  • Genzyme(Sanofi)의 현재 줄기세포 임상시험
  • Teva의 현재 줄기세포 임상시험
  • MedImmune의 현재 줄기세포 임상시험
  • Janssen의 현재 줄기세포 임상시험
  • Seattle Genetics의 현재 줄기세포 임상시험
  • Baxter Healthcare의 현재 줄기세포 임상시험
  • InCyte Corp의 현재 줄기세포 임상시험

제4장 줄기세포, 파괴적 기술, Drug Discovery 및 독성 시험

  • 서론
  • 사례 연구 : Genentech와 줄기세포 기술
  • 3D 배양 시스템
  • 줄기세포와 High Throughput Screening
  • 줄기세포의 유전적 불안정성
  • Comprehensive in Vitro Proarrhythmia Assay(CiPA) & 심근세포
  • PGE(Precise Genome Editing) 및 iPSC의 커플링
  • 줄기세포 & 독성 시험
  • 줄기세포 질환 모델
  • 인간 질환 특유 표현형의 정의
  • 줄기세포 유래 세포 & 약제 스크리닝용 조직의 이점

제5장 줄기세포 바이오마커

  • 다능성 줄기세포 바이오마커
  • 간엽 줄기세포 바이오마커
  • 신경 줄기세포 바이오마커
  • 조혈모세포 바이오마커

제6장 줄기세포 제품의 제조

  • 줄기세포 제품의 제조 전략
  • 줄기세포 제품의 바이오프로세스 경제
  • 자본 투자
  • 상품 원가
  • 바이오프로세스 경제의 촉진요인 & 전략 등

제7장 투자 & 자금

  • 투자자는 세포 & 유전자 치료 기업으로부터 무엇을 원하고 있는가?
  • 무엇이 좋은 투자가 되는가?
  • 투자를 받지 않는 것은 어떤 종류의 기업인가?
  • 세계의 자금
  • 세포 & 유전자 치료에 대한 투자가 진행 등

제8장 재생의료 시장 분석·예측

  • 시장 개요
  • 세계의 빈도 분석
  • 재생의료의 경제
  • 시장 애플리케이션 & 재생 치료의 기회
  • 세계의 금융정세 등

제9장 줄기세포 시장 분석·예측

  • 자가이식 & 동종이계 세포 시장 분석
  • 줄기세포 시장 : 지역별
  • 줄기세포 제품의 예측 : 치료 적응증별
  • 줄기세포 시약 시장의 동향

제10장 조직공학 시장 분석·예측

  • 지역 분석·예측
  • 지역 분석 : 기업 점유율별
  • 조직공학의 임상시험 적응증 분석·예측

제11장 바이오뱅크 시장 분석

  • 세계의 제대혈 은행 수 증가
  • 세계의 바이오뱅크 기업 부문 분석 & 내역
  • 동종이계 vs. 자가이식의 빈도
  • 바이오뱅크 시장 분석·예측
  • 주요 세계 기업

제12장 세계 재생의료 시장의 접근 & 과제

  • 미국의 재생의료 시장
  • 일본의 재생의료 시장
  • 중국의 재생의료 시장
  • 한국의 재생의료 시장

제13장 세포·CAR T요법

  • 면역치료에서 세포치료 및 CAR-T(Chimeric Antigen Receptor T Cells) 관련 과제
  • 면역치료에 관한 규제, 미국의 CAR-T 및 TCR 면역 규제 포함
  • 일본의 세포치료 & 면역치료 규제
  • 유럽의 세포치료 & 면역치료 규제
  • 면역치료의 제조
  • 공급망 & 물류
  • 가격 & 비용 분석

제14장 기업 개요

KSA 18.06.18

영문목차

This analysis and forecast provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $66 billion by 2022, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2022. Tissue engineering is forecast to grow at a CAGR of x% to 2022 and potentially reach $x billion. This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 680 pages.

  • An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.
  • Global regenerative medicine market, global breakdown, application breakdown and leading market players
  • Detailed account of the stem cell industry market by geography, indication and company profiles
  • Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine
  • Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies.
  • Insight into the biobanking industry globally and its impact on the overall market
  • Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies
  • Financial market forecast through 2022 with CAGR values of all market segments outlined in the objective
  • SWOT analysis of the global market
  • Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe

Key Questions Answered in this Report:

  • What is the global market for regenerative medicine from 2016 to 2022?
  • What is the global market for regenerative medicine by geography, through 2022?
  • What is the global market for regenerative medicine by indication, through 2022?
  • What is the global market for the stem cell industry from 2016 to 2022?
  • What is the global market for the stem cell industry by geography, through 2022?
  • What is the global market for the stem cell industry by indication, through 2022?
  • What disruptive technology is advancing the overall regenerative medicine market?
  • What are the major company players in the regenerative medicine, stem cells, tissue engineering and CAR-T industries?
  • What types of clinical trials are currently being performed by stakeholders and major players?
  • What are the strengths, weaknesses, opportunities and threats to the market?
  • Which geographic markets are dominating the space?
  • What are the advantages and disadvantages of the allogenic and autologous stem cell industry?
  • What are the main driving forces of this space?
  • What are the main restraints of the regenerative medicine industry as a whole?
  • What is the current environment of the global cord blood bank industry?
  • What are the global access challenges of the regenerative medicine market?
  • What is the space like in Japan, China, South Korea, USA and Europe?
  • What are the main challenges associated with CAR T therapy?
  • When will the first CAR T therapeutics be approved?
  • What are the current regulations for immunotherapies in USA, Europe & Japan?
  • What are the main manufacturing steps in CAR T therapy?
  • What challenges lie ahead for CAR T production?

Table of Contents

1.0. Report Synopsis

  • 1.1. Objectives of Report
  • 1.2. Executive Summary
  • 1.2. Key Questions Answered in this Report
  • 1.3. Data Sources and Methodology

2.0. Introduction

  • 2.1. Gurdon and Yamanaka Share the Nobel Prize
  • 2.2. Stem Cell Clinical Trials: Initiated in 2010
  • 2.3. Types of Stem Cells
  • 2.4. Adult (Tissue) Stem Cells
  • 2.5. Pluripotent Stem Cells
  • 2.6. Somatic Cell Nuclear Transfer (SCNT)
  • 2.7. Induced pluripotent Stem Cells (iPSC)
  • 2.8. Mesenchymal Cells
    • 2.8.1. MSCs in the Bone Marrow Stroma
    • 2.8.2. Isolation, Marker Specificity and Functional Properties of MSCs
    • 2.8.3. Oxygen Concentration and MSC Culture
    • 2.8.4. Assays to Define MSCs
    • 2.8.5. Differentiation Potential of MSCs
    • 2.8.6. Therapeutic Potential of MSCs
    • 2.8.7. Mesenchymal Stem Cells & Chronic Disease
    • 2.8.8. MSCs and Amylotrophic Lateral Sclerosis
    • 2.8.9. MSCs and Parkinson's Disease
    • 2.8.10. MSCs and Alzheimer Disease
    • 2.8.11. MSCs and Rheumatoid Arthritis
    • 2.8.12. MSCs and Type 1 Diabetes
    • 2.8.13. MSCs and Cardiovascular Disease
  • 2.9. Hematopoietic Stem and Progenitor Cells
    • 2.9.1. In Vivo Assays for Hematopoietic Stem Cells
    • 2.9.2. In Vitro Assays for Hematopoietic Stem and Progenitor Cells
    • 2.9.3. Isolation of Hematopoietic Stem and Progenitor Cells
    • 2.9.4. Culture of Hematopoietic Cells
    • 2.9.5. Therapeutic uses of Hematopoietic Cells
  • 2.10. Umbilical Cord Stem Cells
  • 2.11. Heart Stem Cells
    • 2.11.1. Cutting Edge Research in Heart Stem Cells
  • 2.12. Mammary Stem Cells
    • 2.12.1. Defining the Mammary Stem Cell
    • 2.12.2. Influence of Model System on Stem Cell Identification
    • 2.12.3. Breast Cancer Stem Cells
  • 2.13. Neural Stem Cells
    • 2.13.1. Identification of Neural Stem Cells
    • 2.13.2. Function of Neural Stem Cells in Vivo
    • 2.13.3. Neural Stem Cell Culture Systems
    • 2.13.4. Isolation Strategies for Neural Stem Cells
    • 2.13.5. Brain Tumour Stem Cells
    • 2.13.6. Cutting Edge Research in Neural Stem Cells
  • 2.14. Stem Cell Applications in Retinal Repair
    • 2.14.1. Embryonic Stem Cells as Retina Therapeutics
    • 2.14.2. Induced Pluripotent Stem Cells as Retina Therapeutics
    • 2.14.3. Adipose Derived Mesenchymal Stem Cells as Retina Therapeutics
  • 2.15. Liver Stem Cells
  • 2.16. Gut Stem Cells
  • 2.16. Pancreatic Stem Cells
  • 2.17. Epidermal Stem Cells

3.0. Stem Cells and Clinical Trials

  • 3.1. Introduction
  • 3.2. Pluripotent Stem Cells
  • 3.3. Limbal Stem Cells
  • 3.4. Neural Stem Cells
  • 3.5. Endothelial Stem or Progenitor Cells
  • 3.6. Placental Stem Cells
  • 3.7. Why Do Stem Cell Clinical Trials Fail?
  • 3.8. What is the Future of Stem Cell Trials?
  • 3.9. Cutting Edge Stem Cell Clinical Trials
  • 3.10. Ocata Therapeutics Current Stem Cell Trials
  • 3.11. CHA Biotech Current Stem Cell Trials
  • 3.12. Pfizer Current Stem Cell Trials
  • 3.13. GSK Current Stem Cell Trials
  • 3.14. Bayer Current Stem Cell Trials
  • 3.15. Mesoblast International Current Stem Cell Trials
  • 3.16. Millennium Pharmaceutical Current Stem Cell Trial
  • 3.17. AstraZeneca Current Stem Cell Trials
  • 3.18. Merck Current Stem Cell Trials
  • 3.19. Chimerix Current Stem Cell Trials
  • 3.20. Eisai Current Stem Cell Trials
  • 3.21. SanBio Current Stem Cell Trials
  • 3.22. Celgene Current Stem Cell Trials
  • 3.23. StemCells Current Stem Cell Trials
  • 3.24. Genzyme (Sanofi) Current Stem Cell Trials
  • 3.25. Teva Current Stem Cell Trials
  • 3.26. MedImmune Current Stem Cell Trials
  • 3.27. Janssen Current Stem Cell Trials
  • 3.28. Seattle Genetics Current Stem Cell Trials
  • 3.29. Baxter Healthcare Current Stem Cell Trials
  • 3.30. InCyte Corp Current Stem Cell Trials

4.0. Stem Cells, Disruptive Technology, Drug Discovery & Toxicity Testing

  • 4.1. Introduction
  • 4.2. Case Study: Genentech and Stem Cell Technology
  • 4.3. 3D Sphere Culture Systems
  • 4.4. Stem Cells and High Throughput Screening
    • 4.4.1. Embryonic Stem Cells
    • 4.4.2. Adult Stem Cells
    • 4.4.3. Opportunities & Challenges
  • 4.5. Genetic Instability of Stem Cells
  • 4.6. Comprehensive in Vitro Proarrhythmia Assay (CiPA) & Cardiomyocytes
  • 4.8. Coupling Precise Genome Editing (PGE) and iPSCs
  • 4.9. Stem Cells & Toxicity Testing
    • 4.9.1. Hepatotoxicity and iPSCs
    • 4.9.2. Cardiotoxicity and iPSCs
    • 4.9.3. Neurotoxicity and iPSCs
  • 4.10. Stem Cell Disease Models
  • 4.11. Defining Human Disease Specific Phenotypes
    • 4.11.1. Molecular Phenotypes for Disease Modelling
    • 4.11.2. Cellular Phenotypes for Disease Modelling
    • 4.11.3. Physiological Phenotypes for Disease Modelling
    • 4.11.4. Parkinson's Disease
    • 4.11.5. Alzheimer's Disease
    • 4.11.6. Amyotrophic Lateral Sclerosis
    • 4.11.7. Huntington's Disease
    • 4.11.8. Spinal Muscular Atrophy
    • 4.11.9. Down Syndrome
    • 4.11.10. Cystic Fibrosis
    • 4.11.11. Colorectal Cancer
  • 4.12. Advantages of Stem Cell Derived Cells & Tissues for Drug Screening

5.0. Stem Cell Biomarkers

  • 5.1. Pluripotent Stem Cell Biomarkers
  • 5.2. Mesenchymal Stem Cell Biomarkers
  • 5.3. Neural Stem Cell Biomarkers
  • 5.4. Hematopoietic Stem Cell Biomarkers

6.0. Manufacturing Stem Cell Products

  • 6.1. Manufacturing Strategies For Stem Cell Products
  • 6.2. BioProcess Economics for Stem Cell Products
  • 6.3. Capital Investment
  • 6.4. Cost of Goods
  • 6.5. Bioprocess Economic Drivers & Strategies
  • 6.6. hPSC Expansion & Differentiation using Planar Technology
  • 6.7. hPSC Expansion using 3D Culture
  • 6.8. Microcarrier Systems
  • 6.9. Aggregate Suspension
  • 6.10. Bioreactor Based Differentiation Strategy
  • 6.11. Integrated hPSC Bioprocess Strategy
  • 6.12. GMP Regulations and Stem Cell Products

7.0. Investment & Funding

  • 7.1. What do Investors Want from Cell & Gene Therapy Companies?
  • 7.2. What Makes a Good Investment?
  • 7.3. What Types of Companies do Not Get Investment?
  • 7.4. Global Funding
  • 7.5. Cell & Gene Therapy Investment Going Forward
  • 7.6. What Cell & Gene Companies are the Most Promising in 2018?
  • 7.7. Insights into Investing in Cell and Gene Therapy Companies

8.0. Regenerative Medicine Market Analysis & Forecast to 2022

  • 8.1. Market Overview
  • 8.2. Global Frequency Analysis
  • 8.3. Economics of Regenerative Medicine
  • 8.4. Market Applications & Opportunities for Regenerative Therapies
    • 8.4.1. Neurological Disease
    • 8.4.2. Autoimmune Disorders
    • 8.4.3. Cardiovascular Disease
    • 8.4.4. Diabetes
    • 8.4.5. Musculoskeletal Disorders
    • 8.4.6. Ocular Disease
    • 8.4.7. Orthopedic Disorders
    • 8.4.8. Wound Healing
  • 8.5. Global Financial Landscape
  • 8.6. Regenerative Medicine Clinical Trial Statistics
  • 8.7. Regenerative Medicine Market Forecast to 2021
  • 8.8. Regenerative Medicine Geographic Analysis and Forecast to 2021
  • 8.9. Regenerative Medicine Geographical Location of Companies
  • 8.10. Regenerative Medicine Technology Breakdown of Companies
  • 8.11. Commercially Available Regenerative Medicine Products
  • 8.12. Major Regenerative Medicine Milestones

9.0. Stem Cell Market Analysis & Forecast to 2022

  • 9.1. Autologous & Allogenic Cell Market Analysis
  • 9.2. Stem Cell Market by Geography
    • 9.2.1. North America
    • 9.2.2. Asia/Pacific
    • 9.2.3. Europe
  • 9.3. Stem Cell Market Forecast by Therapeutic Indication
    • 9.3.1. Orthopedic/Musculoskeletal Stem Cell SubMarket
    • 9.3.2. Cancer Stem Cell SubMarket
    • 9.3.3. Cardiology/Vascular Stem Cell SubMarket Analysis
    • 9.3.4. Wound Healing Stem Cell SubMarket Analysis
    • 9.3.5. Skin Stem Cell SubMarket Analysis
    • 9.3.6. Ocular Stem Cell SubMarket Forecast
  • 9.4. Stem Cell Reagent Market Trends

10.0. Tissue Engineering Tissue Engineering Market Analysis and Forecast to 2022

  • 10.1. Geographical Analysis and Forecast to 2022
    • 10.1.1. North America
    • 10.1.2. Europe
    • 10.1.3. Asia Pacific
  • 10.2. Geographical Analysis by Company Share
  • 10.3. Tissue Engineering Clinical Indication Analysis & Forecast to 2022
    • 10.3.1. Orthopedic and Musculoskeletal
    • 10.3.2. Oncology
    • 10.3.3. Cardiology and Vascular
    • 10.3.4. Dermatology
    • 10.3.5. Oral and Dental

11.0. Biobanking Market Analysis

  • 11.1. Increasing Number of Cord Blood Banks Globally
  • 11.2. Global Biobanking Company Sector Analysis & Breakdown
  • 11.3. Allogenic Versus Autologous Transplant Frequency
  • 11.4. Biobanking Market Analysis & Forecast to 2022
  • 11.5. Major Global Players

12.0. Global Access & Challenges of the Regenerative Medicine Market

  • 12.1. Regenerative Medicine Market in the USA
  • 12.2. Regenerative Medicine in Japan
    • 12.2.1. Financial Investment
    • 12.2.2. Unconventional Company Investment in Regenerative Medicine
  • 12.3. Regenerative Medicine in China
  • 12.4. Regenerative Medicine in South Korea

13.0. Cell and CAR T Therapy

  • 13.1. Challenges Relating to Cell therapy and Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.1.1. Clinical Status of CD19 CAR-T Cells To Date
    • 13.1.2. Clinical and Regulatory Challenges for Development of CAR T Cells
    • 13.1.3. Key Regulatory Challenges Associated with CAR-T Development
    • 13.1.4. Summary of Select CAR-T Products by Juno, Novartis and Kite
    • 13.1.5. Clinical Benefit Versus Toxicity in CD19-Directed ALL Clinical Trials
    • 13.1.6. How to Manage Toxicity of CAR-T Therapy
  • 13.2. Regulations Pertaining to Immunotherapy, including Adoptive Cell Therapy (CAR-T and TCR) Immunotherapy Regulation in the USA
    • 13.2.1. Center for Biologics Evaluation and Research (CBER)
    • 13.2.2. Compliance and Surveillance
    • 13.2.3. Extra Resources on Immunotherapeutics from the FDA
    • 13.2.4. Cellular, Tissue and Gene Therapies Advisory Committee
    • 13.2.5. Consumer Affairs Branch (CBER) Contact in FDA
    • 13.2.6. FDA Regulations Pertaining to Immunotherapies
    • 13.2.7. Case Study Ovarian Cancer Immunotherapy Regulations
      • 13.2.7.1. Efficacy
      • 13.2.7.2. Adverse Effects
    • 13.2.8. Trial Design Considerations for Immunotherapy
    • 13.2.9. Development of Immune-Related Response Criteria (irRC) & Clinical Endpoints Specific to Immunotherapies
  • 13.3. Regulations for Cell Therapy & Immunotherapy in Japan
    • 13.3.1. PMDA and Cell Therapy & Immunotherapy
    • 13.3.2. Increasing the Efficiency in Cell Therapy & Immunotherapy Regulatory Review
    • 13.3.3. Forerunner Review Assignment System
    • 13.3.4. Revised Guidelines for Clinical Evaluation of Anti-Malignant Tumor Agents
    • 13.3.5. Key Contacts Within the PMDA for Cell Therapy & Immunotherapeutics
  • 13.4. European Regulation and Cell Therapy & Immunotherapeutics
    • 13.4.1. Introduction
    • 13.4.2. Challenges for Cell Therapy & Immunotherapy in EMEA
    • 13.4.3. EMA Status on Potency Testing
      • 13.4.3.1. In Vivo Potency Testing
      • 13.4.3.2. In Vitro Potency Testing
      • 13.4.3.3. Viable Cell Count
      • 13.4.3.4. Autologous Cell Based Products
      • 13.4.3.5. Reference Preparation
      • 13.4.3.6. Adjuvant Containing Immunotherapy Products
    • 13.4.4. EMA Status on Identifying hyper, Hypo or non-Responders
    • 13.4.5. Challenges Relating to Biomarkers in Immunotherapy
    • 13.4.6. Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.4.7. Estimating Optimal Cut-Off Parameters
    • 13.4.8. EU-Approved Immunotherapies in Melanoma
    • 13.4.9. Key Contacts Within EMA for Cell Therapy & Immunotherapeutics
  • 13.5. Manufacturing of Immunotherapies
    • 13.5.1. Introduction
    • 13.5.2. Generation of CAR-Modified T Cells
    • 13.5.3. What Co-Stimulation and Activity Domain is Optimal to Use?
    • 13.5.4. Optimizing Cell Culture Media
    • 13.5.5. Manufacturing Lentiviral Vectors
    • 13.5.6. Detection of Integrated CAR-Expressing Vectors
    • 13.5.7. Donor Lymphocyte Infusion Procedure
    • 13.5.8. Ex Vivo Costimulation & Expansion of Donor T Cells
    • 13.5.9. Infusion to the Patient
    • 13.5.10Manufacturing Devices and Instruments Required for Immunotherapy Production
      • 13.5.10.1. Leukapheresis
      • 13.5.10.2. Cell Counters and Analyzer
      • 13.5.10.3. Cell Seeding, Growth and Propagation
    • 13.5.11Good Manufacturing Procedure (GMP) for Immunotherapy
    • 13.5.12Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions
    • 13.5.13Quality Control
    • 13.5.14Regulatory Affairs
    • 13.5.15Key Challenges in Manufacturing
      • 13.5.15.1. Electroporation of T-cells
      • 13.5.15.2. Allogenic CAR T cells
      • 13.5.15.3. Relapse Rates are Critical
      • 13.5.15.4. Antigen Negative Relapse
      • 13.5.15.5. Incorporating Suicide Genes
    • 13.5.16Automation in Cell Therapy Manufacturing
    • 13.5.17Autologous Cell Therapy Manufacture Scale Up
  • 13.6. Supply Chain & Logistics
    • 13.6.1. Introduction
    • 13.6.2. Case Study: Juno Therapeutics
  • 13.7. Pricing & Cost Analysis
    • 13.7.1. Introduction
    • 13.7.2. CAR T Therapy Market Evaluation
    • 13.7.3. Current Deals Within the CAR T Market

14.0. Company Profiles

  • 14.1. Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
    • 14.1.1. Company Background
    • 14.1.2. Products
    • 14.1.3. Financials
    • 14.1.4. Company Strategy
  • 14.2. Athersys
    • 14.2.1. Company Background
    • 14.2.2. Products
    • 14.2.3. Financial Analysis
    • 14.2.4. Company Strategy
  • 14.3. Baxter International (Baxalta, Shire)
    • 14.3.1. Company Background
    • 14.3.2. Financial Analysis
    • 14.3.3. Company Strategy
  • 14.4. Caladrius Biosciences (NeoStem)
    • 14.4.1. Company Details
    • 14.4.2. Products
      • 14.4.2.1. CLBS20
      • 14.4.2.2. CLBS03 Treg Cellular Therapy
      • 14.4.2.3. CLBS12 CD34 Cell Therapy
    • 14.4.3. Financial Analysis
    • 14.4.4. Company Strategy
  • 14.5. Cynata Therapeutics
    • 14.5.1. Company Background
    • 14.5.2. Product Details
    • 14.5.3. Financial Data
    • 14.5.4. Company Strategy
  • 14.6. Cytori Therapeutics
    • 14.6.1. Company Products
    • 14.6.2. Financial Analysis
    • 14.6.3. Company Strategy
  • 14.7. MEDIPOST
    • 14.7.1. Company Details
    • 14.7.2. Company Products
      • 14.7.2.1. CellTree Umbilical Cord Blood Bank
      • 14.7.2.2. CARTISTEM®
      • 14.7.2.3. NEUROSTEM®
      • 14.7.2.4. PNEUMOSTEM ®
    • 14.7.3. Financial Analysis
  • 14.8. Mesoblast
    • 14.8.1. Company Details
      • 14.8.1.1. Unique Features of Mesoblast and its Disruptive Technology
      • 14.8.1.2. Allogeneic Mesenchymal Lineage Adult Stem Cells (MLCs)
      • 14.8.1.3. Mechanism of Action of MLC Products
      • 14.8.1.4. Manufacturing of Mesoblast MLC-Based Products
      • 14.8.1.5. Mesoblast Patent Portfolio
    • 14.8.2. Mesoblast Product Portfolio
      • 14.8.2.1. MSC-100-IV/TEMCELL® for Acute Graft Versus Host Disease (aGVHD)
      • 14.8.2.2. MPC-150-IM - Chronic Heart Failure (CHF)
      • 14.8.2.3. MPC-25-IC for Acute Myocardial Infarction
      • 14.8.2.4. MPC-06-ID - Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD)
      • 14.8.2.5. MPC-300-IV for Biologic-Refractory Rheumatoid Arthritis
      • 14.8.2.6. MPC-300-IV for Diabetic Nephropathy
      • 14.8.2.7. MPC-100-IV for Crohn's Disease
      • 14.8.2.8. MPC-25-Osteo for Spinal Fusion
    • 14.8.3. Mesoblast International Strategic Business Collaborations
    • 14.8.4. Mesoblast Financial Analysis
  • 14.9. NuVasive
    • 14.9.1. Company Details
    • 14.9.2. Biologic Products for the Spinal Surgery Market
      • 14.9.2.1. Formagraft
      • 14.9.2.2. AttraX
      • 14.9.2.3. Propel DBM
      • 14.9.2.4. Osteocel Plus and Pro
    • 14.9.3. Financial Analysis
    • 14.9.4. Company Business Strategy
  • 14.10. Osiris Therapeutics
    • 14.10.1. Company Profile
      • 14.10.1.1. BioSmart Cryopreservation Technology
      • 14.10.1.2. MSC Primer Technology
    • 14.10.2. Products
      • 14.10.2.1. Grafix
      • 14.10.2.2. BIO 4
      • 14.10.2.3. Cartiform
      • 14.10.2.4. Stravix
    • 14.10.3. Company Financial Analysis
    • 14.10.4. Company Strategy
  • 14.11. Plasticell
    • 14.11.1Company Profile
  • 14.12. Pluristem Therapeutics
    • 14.12.1. Company Profile
    • 14.12.2. Products
      • 14.12.2.1. PLacental eXpanded (PLX) Cells
      • 14.12.2.2. PLX-PAD
      • 14.12.2.3. PLX-R18
    • 14.12.3. Financial Analysis
    • 14.12.4. Business Strategy
  • 14.13. Pfizer
    • 14.13.1. Company Profile
  • 14.14. StemCells Inc
    • 14.14.1. Company Profile
    • 14.14.2. HuCNS-SC Platform Technology
    • 14.14.3. Clinical Trial Analysis
    • 14.14.4. Financial Analysis
  • 14.15. STEMCELL Technologies
    • 14.15.1. Company Details
    • 14.15.2. Product Details
  • 14.16. Takara Bio
    • 14.16.1. Company Details
    • 14.16.2. Product Portfolio
      • 14.16.2.1. HF10 Anti-Cancer Therapy
      • 14.16.2.2. TCR Gene Therapy
      • 14.16.2.3. MazF Gene Therapy
    • 14.16.3. Centre for Cell and Gene Processing
    • 14.16.4. Company Financials
    • 14.16.5. Company Strategy
  • 14.17. Tigenix
    • 14.17.1. Company Background
    • 14.17.2. Products
    • 14.17.3. Financial Data
    • 14.17.4. Company Strategy

15.0. SWOT Industry Analysis

  • 15.1. What has Strengthened the Industry Thus Far?
  • 15.2. Allogenic and Autologous Stem Cell Industry SWOT Analysis
  • 15.3. What are the Main Driving Forces of this Space?
  • 15.4. Restraints of the Regenerative Medicine Industry as a Whole
  • 15.5. Industry Opportunities Within this Sector
  • 15.6. USA SWOT Analysis
    • 15.6.1. Growth Opportunities
    • 15.6.2. Drivers
    • 15.6.3. Market Challenges
  • 15.7. UK SWOT Analysis
    • 15.7.1. Growth Opportunities
    • 15.7.2. Drivers
    • 15.7.3. Market Challenges
  • 15.8. South Korea SWOT Analysis
    • 15.8.1. Growth Opportunities
    • 15.8.2. Drivers
    • 15.8.3. Market Challenges
  • 15.9. China SWOT Analysis
    • 15.9.1. Growth Opportunities
    • 15.9.2. Drivers
    • 15.9.3. Challenges
  • 15.10. Japan SWOT Analysis
    • 15.10.1. Opportunities
    • 15.10.2. Market Drivers
    • 15.10.3. Challenges
  • 15.11. Singapore SWOT Analysis
    • 15.11.1. Opportunities
    • 15.11.2. Market Drivers
    • 15.11.3. Challenges

List of Exhibits

  • Exhibit 2.1: Stem Cell Discovery and Development Timeline
  • Exhibit 2.2: Potential Therapeutic Uses of Stem Cells
  • Exhibit 2.3: Embryonic Stem Cell Differentiation
  • Exhibit 2.4: Pluripotent Stem Cells
  • Exhibit 2.5: Clinical Uses of Stem Cells
  • Exhibit 2.6: Illustration of Inner Cell Mass Generation for Stem Cell Culture
  • Exhibit 2.7: Drug Development Strategies for Patient Derived iPSCs
  • Exhibit 2.8: Mesenchymal Stem Cell Lineage Progression & Differentiation
  • Exhibit 2.9: Mesenchymal Stem Cell Differentiation
  • Exhibit 2.10: Potential Therapeutic Effects of MSCs
  • Exhibit 2.11: Hematopoietic Stem Cells & the Formation of Mature Blood Cells
  • Exhibit 2.12: Donor Types for HSC transplantation
  • Exhibit 2.13: Total Number of Stem Cell Donors 1989-Present
  • Exhibit 2.14: Cross Section of Umbilical Cord Sample for Stem Cell Extraction
  • Exhibit 2.15: Umbilical Cord Blood and Wharton's Jelly; Sources of HSCs and MSCs
  • Exhibit 2.16: Comprehensive List of Conditions Treated by Cord Blood Transplants
  • Exhibit 2.17: Cardiac Progenator Cell Populations
  • Exhibit 2.18: Transplanted Cardiac Progenitor Cells: Potential Mechanism of Action in the Myocardium
  • Exhibit 2.19: Mammary Stem Cells in the Presence and Absence of Hormones
  • Exhibit 2.20: Mammary Stem Cell Tree Following Transplantation
  • Exhibit 2.21: Production of Neurons, Astrocytes and Oligodendrocytes from Neural Stem Cells
  • Exhibit 2.22: Physiology of the Eye
  • Exhibit 2.23: Physiological Functions of Each Eye Component
  • Exhibit 2.24: Healthy & Degenerated Retinal Pigment Epithelium
  • Exhibit 2.25: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium
  • Exhibit 2.26: Using Stem Cells to Replace Dysfunctional Retinal Pigment Epithelial Cells
  • Exhibit 2.27: Using Stem Cells to Replace Retinal Nerve Cells
  • Exhibit 2.28: Stem Cells Located Around the Central Vein in the Liver
  • Exhibit 2.29: Gut Stem Cells are Located in the Crypts of Lieberhahn
  • Exhibit 2.30: Localization of Epidermal & Dermal Stem Cells
  • Exhibit 3.1: Current Therapeutic Areas and Disease States with Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.2: Current Geographical Location and Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.3: Current Geographical Location and Number of Stem Cell Clinical Trials, USA
  • Exhibit 3.4: Current Geographical Location and Number of Stem Cell Clinical Trials, Europe
  • Exhibit 3.5: Current Geographical Location and Number of Stem Cell Clinical Trials, East Asia
  • Exhibit 3.6: Select hESC and iPSC-Based Products in Clinical Trials by Disease, Stage and Trial Status
  • Exhibit 3.7: Selected Studies and Key Findings of PSC-Based Therapies in Development for AMD, Diabetes, Liver Disease, Parkinson's and Thalassemia
  • Exhibit 3.8: Ocata Therapeutics Current Stem Cell Trials, Globally
  • Exhibit 3.9: CHA Biotech Current Stem Cell Trials, Globally
  • Exhibit 3.10: Pfizer Current Stem Cell Trials, Globally
  • Exhibit 3.11: GSK Current Stem Cell Trials, Globally
  • Exhibit 3.12: Bayer Current Stem Cell Trials, Globally
  • Exhibit 3.13: Mesoblast International Current Stem Cell Trials, Globally
  • Exhibit 3.14: Millennium Pharmaceutical Current Stem Cell Trials, Globally
  • Exhibit 3.15: AstraZeneca Current Stem Cell Trials, Globally
  • Exhibit 3.16: Merck Current Stem Cell Trials, Globally
  • Exhibit 3.17: Chimerix Current Stem Cell Trials, Globally
  • Exhibit 3.18: Eisai Current Stem Cell Trials, Globally
  • Exhibit 3.19: SanBio Current Stem Cell Trials, Globally
  • Exhibit 3.20: Celgene Current Stem Cell Trials, Globally
  • Exhibit 3.21: StemCells Current Stem Cell Trials, Globally
  • Exhibit 3.22: Genzyme (Sanofi) Current Stem Cell Trials, Globally
  • Exhibit 3.23: Teva Current Stem Cell Trials, Globally
  • Exhibit 3.24: MedImmune Current Stem Cell Trials, Globally
  • Exhibit 3.25: Janssen Current Stem Cell Trials, Globally
  • Exhibit 3.26: Seattle Genetics Current Stem Cell Trials, Globally
  • Exhibit 3.27: Baxter Healthcare Current Stem Cell Trials, Globally
  • Exhibit 3.28: InCyte Corp Current Stem Cell Trials, Globally
  • Exhibit 4.1: Disease Models Generated from iSPC using Genome Editing
  • Exhibit 4.2: Stem Cells Used for Drug Screening
  • Exhibit 4.3: Sucessful Human iPSC Mediate Therapy Cases
  • Exhibit 4.4: Number of US Patients That Could Benefit From Stem Cell Therapeutics
  • Exhibit 4.5: Genentechs Stem Cell Platform for Drug & Toxicity Screening
  • Exhibit 4.6: Key Challenges in Assessing Genetic Instability of Stem Cells
  • Exhibit 4.7: Comprehensive In Vitro Proarrhythmia Assay (CiPA) Components
  • Exhibit 4.8: Ex Vivo Gene Therapy and Stem Cell Technology
  • Exhibit 4.9: Genome Editing and iPSCs
  • Exhibit 4.10: Gene Edited iPSC/hES-Mediated Novel Therapy Development
  • Exhibit 4.11: Comparison of 3D and 2D Cultures of iPSC-Derived Hepatocytes Following Treatment with Toxins, Anti-Proliferative Agents and Other Drugs
  • Exhibit 4.12: Potential Applications of Human iPSCs for Liver Diseases
  • Exhibit 4.13: Myocardial Tissue: Cardiomyocytes, Endothelial Cells and Fibroblasts
  • Exhibit 4.14: Cardiovascular Disease-Specific Human Pluripotent Stem Cell Lines by Genetic Cause and Drug Testing
  • Exhibit 4.15: Culture of Human iPSC-Derived Dopaminergic Neurons over 14 Days
  • Exhibit 4.16: Strategies for Generating Disease Models Using Human Pluripotent Stem Cells (PSCs)
  • Exhibit 4.17: Criteria for Disease Modelling Using Pluripotent Stem Cells
  • Exhibit 4.18: Models of Monogenic Dominant Diseases
  • Exhibit 4.19: Models of Monogenic Recessive Diseases
  • Exhibit 4.20: Models of Monogenic X-linked Recessive Diseases
  • Exhibit 4.21: iPSCs in Neurological Disease Modeling, Drug Screening & Cell Therapy
  • Exhibit 4.22: Advantages and Uses of Intestinal Organoids
  • Exhibit 5.1: Main Biomarkers Associated with Pluripotent Stem Cells
  • Exhibit 5.2: Pluripotent Stem Cell Biomarkers
  • Exhibit 5.3: Main Biomarkers Associated with Mesenchymal Stem Cells
  • Exhibit 5.4: Mesenchymal Stem Cell Biomarkers
  • Exhibit 5.5: Main Biomarkers Associated with Neural Stem Cells
  • Exhibit 5.6: Neural Stem Cell Biomarkers
  • Exhibit 5.7: Main Biomarkers Associated with Hematopoietic Stem Cells
  • Exhibit 5.8: Hematopoietic Stem Cell Biomarkers
  • Exhibit 6.1: Bioprocess Development Considerations for hPSC-Derived Products
  • Exhibit 6.2: Technologies Used for Expansion & Differentiation of hPSC-Derived Cell Products
  • Exhibit 6.3: Comparison of Key Performance Characteristics of Cardiomyocytes, Hepatocytes, Neurons, Neural Progenitor Cells, Endoderm Progenitors and Hepatocytes in Planar & Bioreactor Based Differentiation Protocols
  • Exhibit 6.4: Integrated Expansion & Differentiation of hPSCs Studies by Cell, Process, Cell Density, Process Time and Target Cells Produced
  • Exhibit 6.5: hPSC Bioprocess Strategies, Planar, Segregated 3D & Integrated: Advantages & Disadvantages
  • Exhibit 6.6: Main Objectives of GMP Manufacturing
  • Exhibit 6.7: GMP Facilities Required for Stem Cell Product Manufacuring
  • Exhibit 6.8: Manufacturing Overview of hIPSCs under GMP Regulation
  • Exhibit 6.9: Key Steps in Manufacturing GMP Regulated iPSCs
  • Exhibit 6.10: Characterization and Release Assays for Human iPSCs Manufactured under GMP Conditions
  • Exhibit 6.11: MCB Viral Assays for use on Human iPSCs Bank
  • Exhibit 6.12: Differences Between Autologous & Allogeneic Cell Therapy Models
  • Exhibit 7.1: Selected Venrock Biotech and Healthcare Exits
  • Exhibit 7.2: Stem Cell Funding Bodies, Globally
  • Exhibit 7.3: Stem Cell Societies and Consortiums by Geography
  • Exhibit 7.4: Total Stem Cell NIH Funding 2014-2017
  • Exhibit 7.5: NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.6: Tabular Data NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.7: CIRM Investment Funding by Stem Cell Type
  • Exhibit 7.8: CIRM Stem Cell Project Investment Funding by Therapeutic Area
  • Exhibit 7.9: Promising Cell & Gene Companies
  • Exhibit 8.1: Global Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.2: GeoMap Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.3: Increased Proportion of People Over 65 Through 2050
  • Exhibit 8.4: Percentage of Global Population Aged 65 Plus 2015-2050
  • Exhibit 8.5: Global Alzheimer's Disease Market Forecast 2016-2020
  • Exhibit 8.6: Global Cardiovascular Market Forecast 2016-2020
  • Exhibit 8.7: Global Diabetes Therapy and Device Market Forecast 2016-2020
  • Exhibit 8.8: Bone Graft Global Market Forecast 2016-2020
  • Exhibit 8.9: Bone Graft Global Market Forecast to 2020 by Geography
  • Exhibit 8.10: Total Global Financings of the Regenerative Medicine, Cell and Gene Therapy and Tissue Engineering Sector
  • Exhibit 8.11: Total Global Financing of Regenerative Medicine & Cellular/Gene Therapy by Type
  • Exhibit 8.12: Number of Global Clinical Trials by Phase of Regenerative Medicine, Cell and Gene Therapy Studies, 2015
  • Exhibit 8.13: Number of Global Clinical Trials by Indication of Regenerative Medicine, Cellular & Gene Therapeutics, 2015
  • Exhibit 8.14: Major Clinical Trial Events in Regenerative Medicine 2016
  • Exhibit 8.15: Global Regenerative Medicine Market Value Tabular Forecast 2016-2022
  • Exhibit 8.16: Global Regenerative Medicine Market Value Forecast 2016-2022
  • Exhibit 8.17: Regenerative Medicine Geographic Analysis and Forecast to 2022
  • Exhibit 8.18: Regenerative Medicine Geographic Forecast Table to 2022
  • Exhibit 8.19: Regenerative Medicine Market Share by Geography 2016
  • Exhibit 8.20: Regenerative Medicine Market Share Forecast by Geography 2022
  • Exhibit 8.21: North America Regenerative Medicine Forecast to 2022
  • Exhibit 8.22: European Regenerative Medicine Forecast to 2022
  • Exhibit 8.23: Asia Pacific Regenerative Medicine Forecast to 2022
  • Exhibit 8.24: RoW Regenerative Medicine Forecast to 2022
  • Exhibit 8.25: Geographical Location of Regenerative Medicine Companies
  • Exhibit 8.26: Regenerative Medicine Technology Breakdown of Companies
  • Exhibit 8.27: Number and Geographical Location of Regenerative Medicine, Cellular Therapy & Gene Therapy Companies, Globally
  • Exhibit 8.28: Select FDA-Approved Regenerative Medicine Products by Biologics. Cell Based and Biopharmaceuticals
  • Exhibit 8.29: Regulatory Approved & Commercialized Regenerative Medicine Products Currently on the Market
  • Exhibit 8.30: Major Regenerative Medicine Milestones in 2016
  • Exhibit 9.1: Global Stem Cell Therapy Market Forecast Table 2016-2022
  • Exhibit 9.2: Global Stem Cell Therapy Market Forecast 2016-2022
  • Exhibit 9.3: Stem Cell Market Share by Adult and Embryonic Stem Cells and Stem Cell Banking
  • Exhibit 9.4: Major Clinical Trial Events in Stem Cell Medicine 2016
  • Exhibit 9.5: Stem Cell Geographic Market Share Forecast 2016-2022
  • Exhibit 9.6: Global Stem Cell Market Share by Geographic Region 2016
  • Exhibit 9.7: Global Stem Cell Market Share by Geographic Region 2022
  • Exhibit 9.8: North American Stem Cell Market Forecast 2016-2022
  • Exhibit 9.9: Asia Pacific Stem Cell Market Forecast 2016-2022
  • Exhibit 9.10: European Stem Cell Market Forecast 2016-2022
  • Exhibit 9.11: Rest of the World Stem Cell Market Forecast 2016-2022
  • Exhibit 9.12: Market Share of Top Therapeutic Indications in Stem Cell Space, 2016
  • Exhibit 9.13: Market Share of Top Therapeutic Indications in Stem Cell Space, 2022 Forecast
  • Exhibit 9.14: Stem Cell Market Forecast by Therapeutic Indications 2016-2022
  • Exhibit 9.15: Orthopedic/Musculoskeletal Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.16: Cancer Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.17: Cardiology/Vascular Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.18: Wound Healing Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.19: Skin Stem Cell Products and Sources
  • Exhibit 9.20: Skin Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.21: Ocular Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.22: Current Top Brands Being Used for Stem Cell R&D
  • Exhibit 9.23: Most Frequent Method of Obtaining Stem Cell Lines in R&D
  • Exhibit 9.24: Percentage of Stem Cell Characterization Analysis Kits Used in R&D
  • Exhibit 9.25: Percentage of Stem Cell Differentiation Kits Used in R&D
  • Exhibit 9.26: Most Common Types of Stem Cells Used in R&D by Mouse, Human & Rat Origin
  • Exhibit 10.1: Global Tissue Engineering Market Tabular Forecast to 2021
  • Exhibit 10.2: Global Tissue Engineering Market Forecast to 2021
  • Exhibit 10.3: Global Tissue Engineering Market Forecast by Geographic Region 2016-2022
  • Exhibit 10.4: North America Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.5: Europe Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.6: Asia Pacific Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.7: Geographical Breakdown of Tissue Engineering Companies Globally
  • Exhibit 10.8: Public and Privately Held Tissue Engineering Company Distribution, Globally
  • Exhibit 10.9: Main Players in the Tissue Engineering Market
  • Exhibit 10.10: Main Players in the CAR-T Market
  • Exhibit 10.11: Main Players in the TCR Market
  • Exhibit 10.12: Main Players in the NK Cell Market
  • Exhibit 10.13: Main Players in the TILs Market
  • Exhibit 10.14: Global Tissue Engineering Submarket Breakdown by Market Share 2016
  • Exhibit 10.15: Global Tissue Engineering Submarket Breakdown by Market Share Forecast 2022
  • Exhibit 10.16: Tissue Engineering Submarket Breakdown Forecast Table 2016-2022
  • Exhibit 10.17: Tissue Engineering Submarket Breakdown Forecast 2016-2022
  • Exhibit 10.18: Orthopedics/Musculoskeletal Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.19: Oncology Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.20: Cardiology and Vascular Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.21: Dermatology Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.22: Oral and Dental Tissue Engineering Market Forecast 2016-2022
  • Exhibit 11.1: Number of Stem Cell Donors by Geographical Location
  • Exhibit 11.2: Number and Geographical Location of Global Unrelated Cord Blood Units
  • Exhibit 11.3: Market Share of Companies in the BioBanking Industry
  • Exhibit 11.4: Market Share within Therapeutic Companies in the BioBanking Industry
  • Exhibit 11.5: Market Share within Cell & Tissue Banks in the BioBanking Industry
  • Exhibit 11.6: Percentage of Allogenic & Autologous Transplantations
  • Exhibit 11.7: Percentage Breakdown of Indications using Autologous Umbilical Cord Blood Transplants
  • Exhibit 11.8: Percentage Breakdown of Indications using Allogenic Umbilical Cord Blood Transplants
  • Exhibit 11.9: Global Cord Blood Banking Market Forecast 2016-2022
  • Exhibit 11.10: Stem Cell Biobanking Market Segments
  • Exhibit 11.11: Top Global Cord Blood and Tissue Companies
  • Exhibit 11.12: Important Players in the International Private Cord Bank Market
  • Exhibit 12.1: Key Challenges to the Regenerative Medicine & Cellular/Gene Therapy Market
  • Exhibit 12.2: Company and Indication that will Benefit from New 21st Century Cures Act, USA
  • Exhibit 12.3: Cell and Gene Based Therapy in Japan as Defined by the PMDA
  • Exhibit 12.4: Regulatory System in Japan for Regenerative Medicine and Cell and Gene Therapy Products
  • Exhibit 12.5: Main Stem Cell Research Institutes in China
  • Exhibit 13.1: Selected CD19-directed Product Candidates in Clinical Trials by Costimulatory & Binding Domains, Starting Cell Population, Vector and Ablation Technology
  • Exhibit 13.2: Select CD19-Directed ALL Clinical Trials
  • Exhibit 13.3: Select Anti-CD22 CAR-T Clinical Projects
  • Exhibit 13.4: CBER Compliance and Surveillance Activities
  • Exhibit 13.5: Contacts for the Cellular, Tissue and Gene Therapies Advisory Committee, FDA
  • Exhibit 13.6: Clinical Regulatory Pathway - Conventional Route
  • Exhibit 13.7: Clinical Regulatory Pathway - Option for Rapid Translation
  • Exhibit 13.8: PMDA Total Review Period of Standard Drugs
  • Exhibit 13.9: PMDA Total Review Period of Priority Drugs
  • Exhibit 13.10: Number of Approved Recombinant Protein Products by PMDA 1985-2013
  • Exhibit 13.11: Forerunner Review Assignment System Timeframe
  • Exhibit 13.12: Adaptive Licensing and Accelerated Approval in Japan-US-EU
  • Exhibit 13.13: Key Contacts Within PMDA, Japan
  • Exhibit 13.14: CheckMate 066 Clinical Trial
  • Exhibit 13.15: CheckMate 037 Clinical Trial
  • Exhibit 13.16: Contact Details for EMA Cell Therapy & Immunotherapy Experts
  • Exhibit 13.17: Method of Generating CAR-Modified T Cells
  • Exhibit 13.18: Clinical Activity, Cost Structure and Patient Convenience Flow Chart of CAR-T Therapy
  • Exhibit 13.19: General Technical and Personnel Requirements of a GMP, QC, QA, FDA Regulated Cell Therapy Manufacturing Facility
  • Exhibit 13.20: Technician/Scientific Requirements for CAR T Manufacturing
  • Exhibit 13.21: Selection of Apheresis Instruments Currently on the Market
  • Exhibit 13.22: Selection of Cell Counters and Analyzer Instruments Currently on the Market
  • Exhibit 13.23: Main Objectives of GMP Manufacturing Immunotherapeutics
  • Exhibit 13.24: Main Objectives of Quality Control While Manufacturing Immunotherapeutics
  • Exhibit 13.25: Main Objectives of Regulatory Affairs During Manufacturing Immunotherapeutics
  • Exhibit 13.26: CAR-T Studies Using mRNA Transfection Electroporation
  • Exhibit 13.27: Allogenic Versus Autologous Cell Manufacturing
  • Exhibit 13.28: Challenges for Autologous Cell Therapy Manufacture
  • Exhibit 13.29: Current Company/Institutions with Suicide Gene CAR T Projects
  • Exhibit 13.30: Advantages of Using Automated Cell Therapy Manufacturing
  • Exhibit 13.31: Main Drivers to Implement Automated Cell Therapy Manufacturing
  • Exhibit 13.32: Main Benefits of Automated Cell Therapy Manufacturing
  • Exhibit 13.33: Advantages & Disadvantages of Autologous Cell Therapy Manufacture Scale Up
  • Exhibit 13.34: Streptamer® -Based Magnetic Bead Cell Isolation Exhibit 13.35 Juno Therapeutics Manufacturing Facility Objectives
  • Exhibit 13.36: Annual Cost of Patented Cancer Therapeutics from 2000 to Today
  • Exhibit 13.37: Cost of Nivolumab, Pembrolizumab & Ipilimumab per mg
  • Exhibit 13.38: Current Juno Therapeutics Trials and CAR T Products
  • Exhibit 13.39: Current CAR T Business Deals
  • Exhibit 14.1: MultiStem Platform in Action
  • Exhibit 14.2: Key Advantages of MultiStem
  • Exhibit 14.3: Athersys Product and Clinical Pipeline
  • Exhibit 14.4: Athersys Key Business Strategies
  • Exhibit 14.5: Baxter International Product Revenue by Class
  • Exhibit 14.6: Baxter International Product Revenue by Geography
  • Exhibit 14.7: Baxter International Breakdown of Product Revenue
  • Exhibit 14.8: Caladrius Expertise in Cell Type and Therapeutic Application Portfolio
  • Exhibit 14.9: PCT Caladrius CLBS03 Treg Cellular Therapy Manufacturing Process
  • Exhibit 14.10: Caladrius Revenue 2014-2016
  • Exhibit 14.11: Caladrius Clinical Manufacturing Revenue 2014-2016
  • Exhibit 14.12: Caladrius Process Development Revenue 2014-2016
  • Exhibit 14.13: Cytori Cell Therapy Mechanism of Action in Angiogenesis, Inflammation and Wound Remodeling
  • Exhibit 14.14: Cytori Therapeutics Cell Therapy Clinical Pipeline
  • Exhibit 14.15: MediPost Product Pipeline by Indication and Clinical Study Phase
  • Exhibit 14.16: Medipost Sales Figures 2013-2016
  • Exhibit 14.17: CellTree Umbilical Cord Blood Bank Program Details and Pricing
  • Exhibit 14.18: Medipost Revenue Share by Product Category 2016
  • Exhibit 14.19: Medipost Sales Revenue by Product Category 2012-2016
  • Exhibit 14.20: Medipost Umbilical Cord Blood Bank Revenue 2012-2016
  • Exhibit 14.21: Medipost Stem Cell Drug Sales Revenue 2012-2016
  • Exhibit 14.22: Medipost R&D Investment 2012-2016
  • Exhibit 14.23: Mesenchymal Lineage Adult Stem Cells (MLCs) Secrete a Variety of Immunomodulatory Molecules
  • Exhibit 14.24: Mesoblast Mesenchymal Lineage Adult Stem Cell (MLC) Functional Properties
  • Exhibit 14.25: Mesoblast Expanion and Immune Privilege of MLC Technology
  • Exhibit 14.26: Mesoblast Complementary Technology Platforms
  • Exhibit 14.27: Mechanism of Action of MPC-150-IM, MPC-06-ID, MPC-300-IV, TEMCELL(R)HS. Inj. and MSC-100-IV and MPC-25-OSTEO
  • Exhibit 14.28: Mesoblast MLC-Based Product Manufacturing and Distribution Process
  • Exhibit 14.29: Mesoblast Patent Portfolio with Expiration and Validity through 2035
  • Exhibit 14.30: Mesoblast Tier 1 and Tier 2 Product Candidates by Program and Clinical Stage
  • Exhibit 14.31: Mesoblast Lead Product MSC-100-IV/TEMCELL HS Inj
  • Exhibit 14.32: MSC-100-IV Treatment in Children with SR-aGVHD who Failed Other Modalities
  • Exhibit 14.33: MPC-300-IV for Treatment of Chronic Inflammatory Diseases
  • Exhibit 14.34: Mesoblast International Strategic Business Collaborations
  • Exhibit 14.35: Mesoblast FY2015 Share Price and Financial Analysis
  • Exhibit 14.36: Mesoblast Revenue Generated FY2014-FY2015
  • Exhibit 14.37: Mesoblast R&D Expenditure FY2014-FY2015
  • Exhibit 14.38: NuVasive Biologics Portfolio
  • Exhibit 14.39: NuVasive Global Revenue 2013-2015
  • Exhibit 14.40: NuVasive NON GAAP Operating Profit Margin 2013-2015
  • Exhibit 14.41: NuVasive Spinal Surgery Product and Biologic Revenue Breakdown 2013-2015
  • Exhibit 14.42: NuVasive USA and International Revenue Breakdown 2015
  • Exhibit 14.43: NuVasive Corporate Strategy Going Forward
  • Exhibit 14.44: Osiris Therapeutics Current Product Portfolio
  • Exhibit 14.45: Osiris Therapeutics Product Pipeline by Indication, Preclinical, Clinical and Market Stage
  • Exhibit 14.46: Exhibit Plasticel Partnerships and Collaborations with Industry and Academic Institutions
  • Exhibit 14.47: Pluristem Therapeutics Company Pipeline Portfolio by Product, Indication, Location & Phase
  • Exhibit 14.48: Pluristem Therapeutics Production of PLX-PAD & PLX-R18
  • Exhibit 14.49: Pluristem Therapeutics Revenue 2013-2015
  • Exhibit 14.50: Pluristem Therapeutics R&D Costs 2013-2015
  • Exhibit 14.51: Pfizer Stem Cell Policy
  • Exhibit 14.52: StemCell Inc Manufacturing Steps of Hu-CNS-SC Product
  • Exhibit 14.53: STEMCELL Technologies Product Portfolio
  • Exhibit 14.54: STEMCELL Technologies Brand Portfolio
  • Exhibit 14.55: Takara Bio Sales Revenue 2014-2019
  • Exhibit 14.56: Takara Bio Operating Sales 2014-2019
  • Exhibit 14.57: Takara BioIndustry Sales Revenue 2014-2018
  • Exhibit 14.58: Takara Bio Sales by Geographic Region FY2016
  • Exhibit 14.59: Tigenix Key Intellectual Property Patent Portfolio
  • Exhibit 14.60: Comprehensive List of Companies in the Stem Cell & Regenerative Medicine Industry
  • Exhibit 15.1: Advantages, Weaknesses, Opporunities & Threats of Allogenic & Autologous Stem Cells
  • Exhibit 15.2: Opportunistic Therapeutic Indications as Decided by Senior Key Opinion Leaders
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research